






STAT3 inhibition of cholangiocarcinoma cell lines 
reduces viability and restricts the release of 
immunosuppressive cytokines in vitro. 
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Cholangiocarcinoma (CC) is the malignant transformation of epithelial cells originating from the 
bile ducts. This cancer has an abysmal 3 year survival rate of only 10% and is typically 
unresponsive to standard surgical and chemotherapeutic practices7. Therefore, novel treatment 
strategies are desperately needed against this malignancy. One important feature of CC cells is 
their autocrine secretion of interleukin-6 (IL-6)6,9,10. The secretion of IL-6 can activate numerous 
pro-oncogenic signaling pathways including STAT3 within the tumor cell, while simultaneously 
promoting immunologic changes in patients with advanced disease. We hypothesized that 
inhibition of Signal-Transducer and Activator of Transcription-3 (STAT3) pathway may elicit a 
dual effect by promoting apoptosis of human BC cell lines, and limiting the secretion of 
immunosuppressive cytokines from these cells. A panel of human CC cell lines (n=7) with 
various genotypic profiles demonstrated secretion of IL-6 (range 0-6593 pg/mL). Six of the 
seven lines assessed had constitutively phosphorylated STAT3 as determined by western blot. 
A novel small molecule inhibitor, FLLL100, can directly inhibit Tyr705 phosphorylation within the 
SH2 domain of STAT3, and induced apoptosis in the CC cell lines regardless of genotypic 
profile. These effects were observed within 24 hours of drug exposure at micromolar 
concentrations. Immunoblot analysis of PARP cleavage confirmed apoptosis. Exposure of CC 
cell lines to FLLL100 resulted in decreased secretion of IL-6 in culture supernatants. Together, 
these data indicate that the IL-6/STAT3 signaling axis plays a role in human CC survival and 
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Cholangiocarcinoma is a malignant tumor characterized by late clinical presentation and 
lack of response to traditional therapeutic regimens10. The mortality rate from this disease is 
high because of its aggressive and elusive nature. The majority of patients are diagnosed with 
unresectable disease, and the overall five year survival rate is less than 5%10. There are 
approximately 20,000 new diagnoses annually in the United States7.  The number of people 
affected globally each year is even larger7,10.  The most frequent genetic alterations among 
cholangiocarcinomas are KRAS and TP53, although reported genetic alterations vary 
greatly10,19. Cholangiocarcinomas often exhibit a dependence upon the IL-6/STAT3 signal 
transduction pathway6,10.  
Signal Transducer and Activator of Transcription-3 (STAT3) is a transcription factor 
critically involved in the proliferation, survival, metastasis and immune evasion of cancer 
cells1,2,4,6,21. Activation of the STAT3 pathway can be intrinsic or extrinsic due to genetic 
alterations or environmental stimuli including UV radiation, chemical carcinogens or genetic 
alterations, respectively3,22. Additionally, STAT3 signaling is induced by a variety of inflammatory 
cytokines, including Interleukin-6 (IL-6) activation of receptor associated tyrosine kinases, often 
of the Janus kinase (JAK) family3, 6.  STAT3 is also known to be activated by a variety of growth 
factors, including vascular endothelial growth factor (VEGF)3, 22. Several oncoproteins also 
activate STAT3, including SRC and ABL4, 21, 22. Upon activation, phosphorylated STAT3 
molecules dimerize and translocate to the nucleus. It is possible for activated STAT3 molecules 
to form heterodimers with other family proteins and translocate to the nucleus3, 4, 22. STAT3 
activity is normally rapid and transient, due to regulation by several inhibitory molecules, 





Figure 1.STAT3 Pathway. A cytokine or growth factor binds to receptor on the cell membrane. The receptor 
activates TYK2 or JAK. Activated kinase phosphorylates STAT3. pSTAT3 dimerizes and translocates to the 
nucleus. The prodrug FLLL100P is cleaved in vivo into the active drug FLLL100. FLLL100 inhibits the 
phosphorylation of STAT3. 
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In cancer cells, STAT3 remains constitutively activated, leading to production of gene products 
promoting proliferation, survival, angiogenesis and immunosuppression6, 10, 22.  
Inflammation has been implicated as a risk factor in a variety of cancers including 
cholangiocarcinoma. It has been previously characterized that Interleukin-6 (IL-6) is an 
important cytokine to cholangiocarcinoma6, 10. IL-6 activates the STAT3 pathway, which is 
known to cross-talk with other know cancer pathways including the MAPK pathway and the Ras 
and RAF proteins. Phosphorylated STAT3 further activates the STAT3 pathway in a positive 
feedback loop. As previously stated, STAT3 activation promotes proliferation, angiogenesis and 
survival22, and it also promotes production of IL-6, IL-10, and other immunosuppressive 
factors6,4, 22.  
IL-6/STAT3 signaling has an immunosuppressive effect. Increased STAT3 activation 
promotes the generation of immature myeloid cells and increases the number of immature 
dendritic cells. STAT3/IL-6 signaling upregulates myeloid derived suppressor cell generation 
and increases generation of T- regulatory cells 17, 22. It has been previously shown that ablation 
of STAT3 signaling significantly inhibits tumor growth11, 22. Additionally, cells transformed with 
STAT3-C have been characterized as tumorigenic4. STAT3-C is a constitutively activated 
STAT3 molecule made by substituting cysteine residues for specific amino acids in the SH2 
domain of the STAT3 molecule4. We believe that STAT3 is a good target for inhibition in 
cholangiocarcinoma, leading to growth inhibition and apoptosis. 
In the search for specific STAT3 inhibitors, some data suggest that natural products may 
offer a starting point for drug discovery. Previously, curcumin was of great interest in cancer 
research 20. Curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, has been 
shown to experimentally inhibit a variety of targets including STAT3, and exhibits 
chemopreventive and therapeutic properties in experimental cancer models5. The poor 
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bioavailability of curcumin led to the development of analogs. These analogs, based on the 
diketone form of curcumin, were predicted to interact with the SH2 domain of STAT3 and 
prevent STAT3 homodimerization based on computational modeling15. As seen in Figure 2, 
each successive analog of curcumin has been modified slightly.  Previously, our laboratory has 
characterized the effects of two curcumin analogs, FLLL32 and FLLL62, in melanoma and renal 
cell carcinoma1, 2. We have demonstrated that FLLL32 and FLLL62 are specific inhibitors of the 
JAK2-STAT3 pathway, which induces apoptosis in melanoma cell lines A375 and Hs294T1. 
Both compounds bind to the STAT3 SH2 domain, blocking homodimerization of Tyr705 
phosphorylated STAT3 proteins and resulting STAT3 activation2. Based on these studies, a 
novel analog of curcumin, FLLL100, was designed in an effort to overcome the limited solubility 
and bioavailability of FLLL32 and FLLL62 (Figure 2). FLLL100P is a novel prodrug that has 
been modified with a phosphate group, which will be cleaved in vivo into the drug FLLL100. This 
modification is hypothesized to overcome the limitations in solubility seen in previous analogs. 
Before investigating the effects of FLLL100P in vivo, the effects of FLLL100 will be investigated 
in cholangiocarcinoma cell lines. The effects of STAT3 inhibition in human cholangiocarcinoma 
have not previously been characterized. 
 
Hypothesis 
We hypothesize that inhibition of the STAT3 pathway may elicit a dual effect by 
promoting apoptosis of human cholangiocarcinoma cell lines, and limiting the secretion of 
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Figure 2. Curcumin and derivatives. Poor bioavailability of curcumin led to the development of a series of 
analogs at The Ohio State University College of Pharmacology. The effects of FLLL32 and FLLL62 have been 
previously characterized in melanoma, renal, and pancreatic cancer cell lines as pro-apoptotic and anti-
proliferative. FLLL32 and FLLL100 are rapidly cleared in vivo and FLLL100P maintains concentration in the 




Cell Culture  
 Human cholangiocarcinoma cell lines HuCCT1, HuH28, WITT were a kind gift from Dr. 
Tushar Patel (Mayo Clinic), and MzCha1 was a kind gift from Dr. Shannon Glaser (Texas A&M 
Health Science Center). HuCCT1, HuH28, WITT, SNU-245, SNU-478 and SNU-1196 cells were 
cultured in RPMI-1640 media containing 10% FBS, 10mM L-glutamine, and antibiotics. Mz-
Cha1 cells were cultured in CMRL media containing 10% FBS, 10 mM L-glutamine, and 
antibiotics. Cells were plated and treated with varying concentrations of FLLL100 for 24 or 48 
hours. SNU-245, SNU-478, SNU-869, and SNU-1196 were purchased from the Korean Cell 
Line Bank (Seoul, Korea). 
FLLL100 
 FLLL100 was synthesized in the laboratory of Dr. James Fuchs from the Ohio State 
University suspended in DMSO at stock concentration of 20 μM for in vitro studies. 
Western Blot Analysis  
Lysates were prepared from cell lines using Laemmli buffer and assayed from protein 
expression by western blot analysis with antibodies (Ab) to STAT3, pSTAT3 (Tyr705), pSTAT1, 
pSTAT5, STAT1, STAT5, PARP, β-actin (Cell Signaling Technology) as previously described 
by12. Following incubation with the appropriate horse-radish-peroxidase-conjugated secondary 
Ab, immune complexes were detected using SuperSingal® West Pico Chemiluminescent 
Substrate (Thermo Scientific).   
Cellular Growth Assay 
Cholangiocarcinoma cells were seeded in 96-well plates (HuCCT1 3x103 cells/well, 
HuH28 3x103 cells/well, WITT 3x103 cells/well, MzCha1 3x103 cells/well, SNU 245 6x103 
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cells/well, SNU 478 2x103 cells/well, SNU 1196 4x103 cells/well) in triplicate and allowed to 
adhere overnight. Fresh media containing FLLL100 was added to each well at various 
concentrations (Range = 0 - 10 μM) and cells were incubated at 37ºC/5% CO2 for 72 hours. 
Cells treated with DMSO (vehicle) served as controls. At this time, the percentage of cell growth 
was evaluated using the MTS assay (CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay, Promega) and quantified by determining the optical density at 595 nm using a Bio-Rad 
iMark™ microplate reader. 
Analysis of Apoptosis via Flow Cytometry 
Cholangiocarcinoma cells were seeded in 6-well plates (HuCCT1 1x106 cells/well, 
HuH28 1x106 cells/well, WITT 1x106 cells/well, MzCha1 1x106 cells/well, SNU 245 1x105 
cells/well, SNU 478 1x105 cells/well, SNU 1196 2x105 cells/well) and allowed to adhere 
overnight. Fresh media containing FLLL100 was added to each well at various concentrations 
and cells were incubated at 37ºC/5% CO2 for 72 hours. Cells treated with DMSO (vehicle) and 
untreated cells served as controls. At this time, phosphatidyl serine exposure was assessed in 
tumor cells by flow cytometry using APC-Annexin V and propidium iodide (PI; BD Pharmingen, 
San Diego, CA) as previously described 1, 13, 14. Each analysis was performed utilizing at least 
10,000 events on a FACSCalibur flow cytometer.  
Analysis of cytokines in CC culture supernatants  
Supernatants from CC cultures were assessed for the presence of IL-6 using 
commercial ELISA (R & D Systems, Inc., Minneapolis, MN). Fresh media containing FLLL100 
was added at various concentrations to CC cells and incubated at 37ºC/5% CO2 for 24 hours. 






Majority of Cholangiocarcinoma cell lines display constitutively activated STAT3. 
The STAT proteins are highly homologous and act to transduce signals across the cell 
membrane and as transcription factors at the DNA level4, 21, 22. STAT3 and STAT5 play a major 
role in cancer inflammation, while STAT1 plays a role in anti-tumor immune responses22. These 
pathways can be antagonizing, and represent an area of interest in targeted therapeutic 
interventions. The basal expression of STAT family proteins was assessed in a panel of human 
cholangiocarcinoma cell lines to determine if cholangiocarcinomas would be susceptible to 
FLLL100. In the majority of cell lines (n=6 of 7) detectable basal pSTAT3 levels were observed. 
Only the SNU-245 cell line lacked basal STAT3 phosphorylation.  The amount of basal pSTAT3 
varied among the cell lines, as seen in Figure 3. Basal levels of pSTAT5 were observed in n=3 
cell lines. In contrast, no cell lines had detectable phosphorylation of STAT1, consistent with its 












Figure 3. Basal levels of protein expression in the human cholangiocarcinoma cell 
lines, n=7. In n=6 cell lines, there was some amount of basal expression of pSTAT3. 
There was pSTAT5 expression in n=3 cell lines. In 7 cell lines, there was no detectable 
expression of pSTAT1. β-Actin was used as a loading control.  
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STAT3 phosphorylation decreased with FLLL100 treatment. 
After observing constitutively active STAT3 in the majority of human cholangiocarcinoma 
cell lines, we next determined what effect FLLL100 treatment would have on pSTAT3 
expression. SNU-478 was selected as representative cell line for this experiment, as it had a 
high level of basal pSTAT3 expression. With increasing concentrations of FLLL100, there was a 
decrease in pSTAT3 (Figure 4). Importantly, there was no change in the level of total STAT3 
protein expression. These data indicate that FLLL100 affected phosphorylation events rather 
than transcription or translation of total STAT3 protein. This experiment was replicated in 
additional cell lines and similar effects were observed (data not shown).  
 
FLLL100 exhibits growth inhibition in human CC cell lines. 
We next tested whether FLLL100 could elicit growth inhibitory properties against human 
cholangiocarcinoma cell lines in vitro. We hypothesized that FLLL100 would exhibit potent 
growth inhibitory activity against human cholangiocarcinoma cell lines. In pSTAT3 positive cell 
lines, FLLL100 exhibited growth inhibition to different degrees. The general trend observed was 
a concentration-dependent decrease in percent growth in response to FLLL100 (Figure 5). In 
the SNU-245 cell line, there was no basal pSTAT3 (see figure 3). There was little change in the 
percentage of growth with increasing concentrations of FLLL100 in the SNU-245 cell line. These 














Figure 4. STAT3 expression following treatment with FLLL100. 
With increasing concentrations of FLLL100, there is decreased 
intensity of pSTAT3 observed. Additionally, there is increased PARP 
cleavage at higher concentrations of FLLL100. β-Actin was used as 
a loading control. 
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Figure 5. FLLL100 induces growth inhibition. Cells were treated for 48 hours with increasing 
concentrations of FLLL100. At least 2 biological replicates were performed. With increasing 
concentrations of FLLL100, there is a decrease in growth in n=6 cell lines.  
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FLLL100 induces apoptosis in human CC cell lines.  
After observing the growth inhibitory effect of FLLL100, we investigated whether this 
agent would also promote pro-apoptotic effects. A concentration-dependent increase in 
apoptosis of human CC cell lines was observed following a 48 hour treatment with FLLL100 in 
n=6 of 7 cell lines (Figure 6). There was no observable effect of FLLL100 on apoptosis in the 
SNU-245 cell line, which lacked basal phosphorylation of STAT3. Again, this supports the notion 
that FLLL100 elicited pro-apoptotic activity by interrupting the phosphorylation of STAT3.  
 
IL-6 production is decreased with FLLL100 treatment.  
IL-6 is both an upstream activator and a gene product of the STAT3 pathway10, 16, 21, 22. 
As a result, we tested whether FLLL100 would alter IL-6 secretion from human CC cell lines. 
Many of the human CC cell lines secreted basal levels of IL-6, but the initial concentration 
observed varied greatly between individual cell lines. For example, the HuCCT1 and HuH28 CC 
cell lines secreted the largest basal concentrations of IL-6.  In contrast, SNU-245 CC cell line 
secreted no detectable concentration of IL-6 (data not shown).  Following treatment with 
FLLL100, the concentrations of IL-6 were decreased (Figure 7).  This effect on reduced IL-6 











Figure 6. FLLL100 induces apoptosis in cholangiocarcinoma cell lines. Cells were treated 
for 48 hours with increasing concentrations of FLLL100. At least 2 biological replicates were 


















































CC cell lines 
Figure 7. Decreased IL-6 production following FLLL100 treatment. Cell 
supernatants were collected and IL-6 concentration was assessed. At least two 
biological replicates were performed. With increasing concentration of FLLL100, 





















We observed that STAT3 inhibition produced anti-tumor effects using a novel small 
molecule inhibitor FLLL100. We showed that most human cholangiocarcinoma cell lines have 
basal levels of pSTAT3 present. In the panel shown, only SNU-245 is pSTAT3 negative. We 
demonstrated that FLLL100 inhibits phosphorylation of STAT3 in human cholangiocarcinoma 
cell lines, as seen in representative cell line SNU-478. In SNU-478, the level of pSTAT3 showed 
a decrease with increasing FLLL100 concentrations. Since SNU-245 is pSTAT3 negative, we do 
not expect FLLL100 to have an effect on it. We also showed that FLLL100 induced cytostatic 
and cytotoxic effects. We demonstrated that treatment with FLLL100 inhibits growth and 
induces apoptosis in human cholangiocarcinoma cell lines. We observed that FLLL100 can 
decrease autocrine IL-6 production in human cholangiocarcinoma cell lines. It is possible that 
the decreased production of IL-6 could be due in part to the decreased number of viable cells. 
However, there is a decrease in IL-6 observed at very low concentrations of FLLL100 (2,4 μM) 
as compared to the growth inhibition and apoptosis data, which did not show a decrease or 
increase respectively until higher concentrations of FLLL100 (6, 8, 10uM). This suggests that 
the decrease observed in IL-6 production is real and as a result of FLLL100 treatment, and not a 
side effect of the growth inhibitory or apoptotic effects of FLLL100.  
 We have shown that FLLL100 is novel small molecule inhibitor specific to STAT3. SNU-
245 is a pSTAT3 negative cell line, which served as a useful point of comparison in many of the 
experiments. We expected treatment with FLLL100 to have no effect on SNU-245, because 
FLLL100 acts to inhibit phosphorylation of STAT3 by competitively binding at the Tyrosine 705 
phosphorylation site. There was no change to the percent of growth or apoptosis respectively of 
SNU-245 following FLLL100 treatment. Since it appears that FLLL100 has no effect in the 
absence of pSTAT3, and pSTAT3 is only transiently activated in normal cells, we hypothesize 
that FLLL100 will have no effect on human biliary cells and will specifically target only cancer 
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cells. If FLLL100 also induces apoptosis in human biliary cells, then it will have limited clinical 
potential.  However, our laboratory has previously shown that other curcumin analogs have no 
effect on normal human cells such as melanocytes1,2, and we are hopeful that FLLL100 will not 
affect biliary cells, or any normal human cells.  
We observed that inhibition of the STAT3 pathway elicited a dual effect by promoting 
apoptosis of human cholangiocarcinoma cell lines, and limiting the secretion of 
immunomodulatory cytokines from these cells. STAT3 inhibition has not previously been 
investigated in cholangiocarcinoma, and these results support the pursuit of further 
investigation. As previously described, cholangiocarcinoma patients are in desperate need for 
novel therapeutic options. We believe that STAT3 inhibition could be a viable treatment 
alternative or supplement to patients who are unresponsive to traditional chemotherapy.  Indeed 
prior studies with other STAT3 inhibitors such as Stattic have shown the ability to sensitize cells 
to chemotherapy18. 
 There are several limitations of this project in its current form. First, we have not yet 
completed studies in which normal, non-cancerous cells are treated with FLLL100 as a control. 
This is important because this inhibitor will have no therapeutic application if it is not specific to 
malignant cells. In order for FLLL100 to continue development as a cancer therapy, we must 
demonstrate that it has no effect on normal cells. However, using earlier structural analogs of 
FLLL100, our laboratory has shown that FLLL32 and FLLL62 had no effect on normal 
melanocytes or peripheral blood mononuclear cells from healthy adult donors1, 2. Based on 
these data, we are hopeful that FLLL100 will also have no adverse effects on normal 
cholangiocytes. Second, we have not yet tested this compound in more clinically-relevant 
mouse models of cholangiocarcinoma, which were recently acquired by our laboratory8. We are 
currently studying the best dosing regimen of the prodrug of FLLL100 (FLLL100P) using 
pharmacokinetics. As a result, we have not yet conducted any in vivo experiments. In the future, 
23 
 
we plan to use both these models and an immunosuppressed mouse model where human CC 
cells are injected subcutaneously into the mouse. Although the immunosuppressed mouse 
model would allow us to investigate the potential action of FLLL100P on human CC cells, it 
would limit us in data output. This model would give us no information about the effects of 
FLLL100P on the immune system, which plays an important role in the progression of cancer. 
To be an accurate representation of cholangiocarcinoma in patients, it would be better to use a 
mouse model that spontaneously develops cholangiocarcinoma as a result of genetic mutations 
or an extrinsic factor, which we are planning to do. Third, our experiments did not conclusively 
demonstrate the mechanism of action of FLLL100. We hypothesize that FLLL100 inhibits 
phosphorylation by competitively binding to STAT3 at the tyrosine 705 phosphorylation site. 
While we have a variety of data to support this, we did not pursue any experiments to explicitly 
show it, so it is possible that it is acting on a different protein and triggering the effects we 
observed. One experiment we could use to decisively show the mechanism of action would be 
to transfect human cholangiocarcinoma cells with STAT3-C, a constitutively activated STAT3 
molecule4. In these cells, we would hypothesize that FLLL100 treatment would have no effect 
on proliferation or survival since the phosphorylation site would no longer exist.  
There are still many different experiments to be conducted before FLLL100 would reach 
the patient level. One very essential experiment to conduct would be to investigate the effects of 
FLLL100 on normal cholangiocytes. Before this treatment would be approved for human trials, it 
would be necessary to demonstrate that FLLL100 would have no effect on normal cells.  In 
addition to evaluating the effects of FLLL100 in normal cholangiocytes, there are many 
directions to take this project in the future. For example, this project could go progress to in vivo 
experiments. We have not previously investigated FLLL100 in mice, but our collaborators are 
working on determining the dosing in mice. We hypothesize that the prodrug, FLLL100P, will be 
activated in vivo and show improved solubility as compared to previous analogs.   Additionally, 
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combination experiments could be performed using FLLL100 and either MEK inhibitors or JAK 
inhibitors. As seen in figure 1, these pathways are interconnected, and we believe that 
combination treatments could be even more effective.  
Conclusions 
FLLL100 inhibited STAT3 phosphorylation in human cholangiocarcinoma cell lines. 
Additionally, FLLL100 induced cytostatic and cytotoxic effects. Finally, FLLL100 decreased 
autocrine IL-6 production in human CC cell lines. Future experiments to assess in vivo efficacy 
of FLLL100 should be conducted. We believe that STAT3 represents a relevant target in human 
cholangiocarcinoma.  Cholangiocarcinoma is a rare but brutal disease and there is need for 
novel treatments for these patients as their disease is often diagnosed late and nonresponsive 
to traditional treatments. The majority of cholangiocarcinomas exhibit activated STAT3, as do 
many other cancers, and as such, we believe FLLL100 may hold potential for future drug 
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